| Keyword | CPC | PCC | Volume | Score | Length of keyword |
|---|---|---|---|---|---|
| pembrolizumab adjuvant melanoma nejm | 1.71 | 0.5 | 5314 | 50 | 36 |
| pembrolizumab | 0.29 | 0.1 | 9724 | 59 | 13 |
| adjuvant | 1.39 | 0.2 | 7193 | 5 | 8 |
| melanoma | 0.67 | 1 | 6328 | 67 | 8 |
| nejm | 0.25 | 0.6 | 5061 | 32 | 4 |
| Keyword | CPC | PCC | Volume | Score |
|---|---|---|---|---|
| pembrolizumab adjuvant melanoma nejm | 1.51 | 0.6 | 6514 | 92 |
| neoadjuvant pembrolizumab in melanoma | 1.1 | 0.1 | 544 | 29 |
| adjuvant pembrolizumab stage 2 melanoma | 0.53 | 0.9 | 9944 | 45 |
| adjuvant pembrolizumab melanoma stage ii | 1.57 | 0.3 | 5857 | 28 |
| adjuvant pembrolizumab stage 3 melanoma | 1.76 | 0.2 | 8106 | 98 |
| adjuvant pembrolizumab melanoma stage iii | 1.25 | 0.4 | 2061 | 3 |
| pembrolizumab in metastatic melanoma | 1.8 | 1 | 7853 | 62 |
| pembrolizumab versus nivolumab for melanoma | 1.45 | 1 | 345 | 36 |
| pembrolizumab vs nivolumab melanoma | 1.08 | 0.9 | 1511 | 90 |
| nejm pembrolizumab lung cancer | 1.02 | 0.6 | 373 | 82 |
| pembrolizumab fda approval melanoma | 1.89 | 0.5 | 9240 | 73 |
| nejm pembrolizumab adjuvant renal | 1.48 | 0.8 | 455 | 98 |
| nivolumab and pembrolizumab for melanoma | 1.21 | 0.4 | 1698 | 12 |
| pembrolizumab head and neck cancer nejm | 1.89 | 0.6 | 804 | 42 |
| pembrolizumab success rate melanoma | 1.6 | 1 | 3511 | 90 |
| pembrolizumab adjuvant breast cancer | 0.64 | 1 | 8018 | 58 |
| pembrolizumab renal cell carcinoma nejm | 1.49 | 0.1 | 3209 | 25 |
| pembrolizumab for stage ii melanoma | 1.57 | 0.2 | 7631 | 11 |
| pembrolizumab in neoadjuvant breast cancer | 1.63 | 0.3 | 4956 | 82 |
